Retraction
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine
Paper Information
Record ID:
42788
Journal:
Publication Date:
December 08, 2003
Retraction Date:
February 16, 2023
(2.8 years years ago)
Subjects:
Country:
🇺🇸 United StatesArticle Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (230)
230
Total Citations4
Post-Retraction(1.7%)
226
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
2
Within 1 year
1
After 2+ years
869
Days since retraction (latest)
RECQL1 DNA Repair Helicase: A Potential Therapeutic Target and a Proliferative Marker against Ovarian Cancer
Sakiko Sanada, Kazunobu Futami, Atsumu Terada et al. (12 authors)
PLoS ONE
Open Access
Published: Aug 2013
23 citations
23 citations
3478 days before retraction
RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy
Mohammad Aminur Rahman, A.R.M. Ruhul Amin, Dongsheng Wang et al. (11 authors)
Clinical Cancer Research
Open Access
Published: May 2013
112 citations
112 citations
3549 days before retraction
Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma
Lauren E. Colbert, Sarah B. Fisher, Claire Hardy et al. (19 authors)
Cancer
Open Access
Published: May 2013
120 citations
120 citations
3550 days before retraction
RNAi in Cancer Therapy
Cristian Rodriguez‐Aguayo, Arturo Chávez‐Reyes, Gabriel López-Berestein et al. (4 authors)
Unknown Journal
Published: Apr 2013
1 citation
1 citation
3583 days before retraction
A Retrospective Study of Chemotherapy with Cisplatin Plus Gemcitabine After the Failure of Gemcitabine Monotherapy for Biliary Tract Cancer
Ryo Kameda, Taiki Ando, Shogo Kobayashi et al. (5 authors)
Japanese Journal of Clinical Oncology
Open Access
Published: Apr 2013
11 citations
11 citations
3584 days before retraction
Reply to an analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment
Sarah B. Fisher, Shishir K. Maithel
Cancer
Open Access
Published: Apr 2013
30 citations
30 citations
3590 days before retraction
Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase
Meng Zhang, Jing Wang, Ruyong Yao et al. (4 authors)
International Journal of Gynecological Cancer
Published: Mar 2013
25 citations
25 citations
3634 days before retraction
RNAi in Clinical Studies
P. Kubowicz, Dorota Żelaszczyk, Elżbieta Pękala
Current Medicinal Chemistry
Open Access
Published: Mar 2013
63 citations
63 citations
3639 days before retraction
Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity
S.-y. Wu, Tian-min Chen, William H. Gmeiner et al. (5 authors)
Nucleic Acids Research
Open Access
Published: Feb 2013
14 citations
14 citations
3640 days before retraction
Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein
Yangzom D. Bhutia, Sau Wai Hung, Madeline Krentz et al. (8 authors)
PLoS ONE
Open Access
Published: Jan 2013
73 citations
73 citations
3684 days before retraction
Impact of ABO Blood Types on Survival after Pancreatectomy for Pancreatic Cancer
Tadashi Kayashima, Masafumi Nakamura, Kenoki Ohuchida et al. (10 authors)
Journal of Cancer Therapy
Open Access
Published: Jan 2013
1 citation
1 citation
3698 days before retraction
Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
Jing Xu
Unknown Journal
Published: Jan 2013
3698 days before retraction
Proteomic Comparison of MCF-7 Tumoursphere and Monolayer Cultures
Brian J. Morrison, Marcus L. Hastie, Yadveer S. Grewal et al. (8 authors)
PLoS ONE
Open Access
Published: Dec 2012
28 citations
28 citations
3710 days before retraction
Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy
Ozan Kahramanoğulları, Gianluca Fantaccini, Paola Lecca et al. (5 authors)
PLoS ONE
Open Access
Published: Dec 2012
19 citations
19 citations
3719 days before retraction
A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis
Vincenzo D’Angiolella, Mine Esencay, Michele Pagano
Trends in Cell Biology
Open Access
Published: Nov 2012
96 citations
96 citations
3741 days before retraction
High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer
Elisa Giovannetti, Arjan van der Velde, Niccola Funel et al. (16 authors)
PLoS ONE
Open Access
Published: Nov 2012
70 citations
70 citations
3746 days before retraction
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Elodie Moysan, Guillaume Bastiat, Jean-Pierre Benoı̂t
Molecular Pharmaceutics
Open Access
Published: Sep 2012
203 citations
203 citations
3807 days before retraction
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells
Piyanuch Wonganan, Woon-Gye Chung, Saijie Zhu et al. (6 authors)
Cancer Biology & Therapy
Open Access
Published: Aug 2012
22 citations
22 citations
3851 days before retraction
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin et al. (18 authors)
Investigational New Drugs
Open Access
Published: Jul 2012
27 citations
27 citations
3853 days before retraction
Excision repair cross‐complementing gene‐1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter‐1 expression and prognostic value in biliary tract malignancy
Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel et al. (10 authors)
Cancer
Published: Jul 2012
31 citations
31 citations
3880 days before retraction
An analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma
Sarah B. Fisher, Sameer H. Patel, Pelin Bağcı et al. (8 authors)
Cancer
Open Access
Published: May 2012
45 citations
45 citations
3936 days before retraction
Paper citing RNA interference targeting the M2 subunit of ribon...
Unknown Authors
Unknown Journal
Published: May 2012
3943 days before retraction
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles
Dharmika S.P. Lansakara-P, B. Leticia Rodriguez, Zhengrong Cui
International Journal of Pharmaceutics
Open Access
Published: Mar 2012
45 citations
45 citations
3989 days before retraction
Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
Sau Wai Hung, Hardik Mody, Rajgopal Govindarajan
Cancer Letters
Open Access
Published: Mar 2012
80 citations
80 citations
3992 days before retraction
Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1
Xinyu Zhao, Chunlai Nie, Shufang Liang et al. (6 authors)
Biomedicine & Pharmacotherapy
Published: Feb 2012
10 citations
10 citations
4017 days before retraction
Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma
Ping Han, Zhi-Rui Lin, Li-Hua Xu et al. (9 authors)
Molecular Medicine Reports
Open Access
Published: Feb 2012
16 citations
16 citations
4018 days before retraction
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
Mohammad Aminur Rahman, A.R.M. Ruhul Amin, Xu Wang et al. (14 authors)
Journal of Controlled Release
Open Access
Published: Feb 2012
87 citations
87 citations
4026 days before retraction
CHEMOSENSITIZATION OF HEPATOCELLULAR CARCINOMA TO GEMCITABINE BY NON-INVASIVE RADIOFREQUENCY FIELD-INDUCED HYPERTHERMIA
Mustafa Raoof
Unknown Journal
Published: Jan 2012
4064 days before retraction
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Hao Xie, Jingmei Lin, Dafydd G. Thomas et al. (5 authors)
PubMed
Published: Jan 2012
6 citations
6 citations
4064 days before retraction
Targeting Tumors and the Kidney with siRNA Nanoparticles and Evaluation of Extracellular MicroRNA-based Methodologies to Track Their Activity
Jonathan E. Zuckerman
Unknown Journal
Published: Jan 2012
4064 days before retraction
KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
Yasuhiro Yoshida, Toshiyuki Tsunoda, Keiko Doi et al. (13 authors)
PubMed
Published: Jul 2011
36 citations
36 citations
4248 days before retraction
Paper citing RNA interference targeting the M2 subunit of ribon...
Unknown Authors
Unknown Journal
Published: May 2011
4284 days before retraction
Personalized Cancer Approach: Using RNA Interference Technology
John Nemunaitis, Donald D. Rao, Shi‐He Liu et al. (4 authors)
World Journal of Surgery
Published: May 2011
8 citations
8 citations
4301 days before retraction
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma
Jun Sato, Takashi Kimura, Takuro Saito et al. (8 authors)
Journal of Hepato-Biliary-Pancreatic Sciences
Published: Mar 2011
40 citations
40 citations
4341 days before retraction
Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—A review
Sameer A. Dhayat, Wolf Arif Mardin, Soeren Torge Mees et al. (4 authors)
International Journal of Cancer
Open Access
Published: Mar 2011
31 citations
31 citations
4355 days before retraction
Small Interfering RNA for Effective Cancer Therapies
Xiaohui Wang, Y. Chen, Jie Ren et al. (4 authors)
Mini-Reviews in Medicinal Chemistry
Published: Feb 2011
13 citations
13 citations
4398 days before retraction
Molecular predictors of gemcitabine response in pancreatic cancer
Ioannis A. Voutsadakis
World Journal of Gastrointestinal Oncology
Open Access
Published: Jan 2011
71 citations
71 citations
4429 days before retraction
Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
Teppei Morikawa, Daichi Maeda, Haruki Kume et al. (5 authors)
Histopathology
Published: Dec 2010
95 citations
95 citations
4460 days before retraction
SiRNA Delivery Vehicles
Aliasger K. Salem, Mark A. Behlke
Unknown Journal
Published: Nov 2010
1 citation
1 citation
4461 days before retraction
Advanced or Metastatic Pancreatic Cancer: Molecular Targeted Therapies
Soley Bayraktar, Caio Rocha‐Lima
Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
Published: Nov 2010
35 citations
35 citations
4490 days before retraction
Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells
Mаhmoud Youns, Thomas Efferth, Jörg D. Hoheisel
European Journal of Pharmacology
Published: Oct 2010
25 citations
25 citations
4501 days before retraction
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide
Jonathan E. Zuckerman, Teli Hsueh, Richard C. Koya et al. (5 authors)
Journal of Investigative Dermatology
Open Access
Published: Oct 2010
41 citations
41 citations
4508 days before retraction
Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
Hayato Fujita, Kenoki Ohuchida, Kazuhiro Mizumoto et al. (13 authors)
Neoplasia
Open Access
Published: Oct 2010
147 citations
147 citations
4521 days before retraction
Challenges of drug resistance in the management of pancreatic cancer
Rizwan Masood Sheikh, Naomi Walsh, Martin Clynes et al. (5 authors)
Expert Review of Anticancer Therapy
Open Access
Published: Oct 2010
49 citations
49 citations
4521 days before retraction
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro
Teppei Morikawa, Rumi Hino, Hiroshi Uozaki et al. (8 authors)
Human Pathology
Published: Sep 2010
77 citations
77 citations
4539 days before retraction
Vaccinia Virus–Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis
Don B. Gammon, Branawan Gowrishankar, Sophie Duraffour et al. (6 authors)
PLoS Pathogens
Open Access
Published: Jul 2010
86 citations
86 citations
4606 days before retraction
Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck
Yong Liu, Xin Zhang, Yuanzheng Qiu et al. (11 authors)
Journal of Cancer Research and Clinical Oncology
Published: Jul 2010
34 citations
34 citations
4607 days before retraction
Delivery of RNAi mediators
Lance P. Ford, Masoud Toloue
Wiley Interdisciplinary Reviews - RNA
Open Access
Published: Jun 2010
11 citations
11 citations
4641 days before retraction
The role of 5'-nucleotidases and Deoxynucleoside Kinases in Responses to Nucleoside Analogues
Saeedeh Mirzaee
Unknown Journal
Published: Apr 2010
4675 days before retraction
A preliminary result of three-dimensional microarray technology to gene analysis with endoscopic ultrasound-guided fine-needle aspiration specimens and pancreatic juices
Koji Nonogaki, Akihiro Ito, Hiroki Kawashima et al. (15 authors)
Journal of Experimental & Clinical Cancer Research
Open Access
Published: Apr 2010
6 citations
6 citations
4680 days before retraction
Quick Stats
Total Citations:
230
Years Since Retraction:
2.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025